Mishcon de Reya has advised fund managers Woodford Investment Management, founded by Neil Woodford CBE, and Arthurian Life Sciences, founded by Sir Chris Evans, on their investment in CeQur SA. CeQur SA is a company dedicated to helping people with type 2 diabetes manage their disease by developing and commercializing simple drug delivery devices. The company's lead product, PaQ, is a wearable insulin device that delivers insulin for 3 days at a time. Clinical studies indicate that PaQ will provide a superior alternative to injection therapy.
The latest fundraising will facilitate ongoing clinical and regulatory activities as well as commercial scale up for the PaQ. The aim is to build a high-growth business in the emerging category of simple and cost-effective insulin infusion. CeQur will be launching the product commercially in selected markets in Europe next year and in America in 2017.
The Mishcon de Reya team was led by Corporate Partner Michael Nouril, assisted by Corporate Solicitors James Spencer and Pippa Williamson and Trainee Solicitor Tim Froy.